Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Wesfarmers (ASX:WES) share price rises with likely API (ASX:API) takeover

The Wesfarmers (ASX:WES) share price rose by 2% today as it's in prime position to take over Australian Pharmaceutical Industries (ASX:API). 

The Wesfarmers Ltd (ASX: WES) share price rose by 2% today as it seemed that it’s in prime position to take over Australian Pharmaceutical Industries Ltd (ASX: API).

What happened today?

The other contender for API has been Sigma Healthcare Ltd (ASX: SIG). However, Sigma announced today that it will not proceed with its current proposal.

Sigma’s board still thinks that a merger with API is a very strong proposal, particularly due to the $45 million of operational synergies per year that it thinks would have been created.

However, after further assessment, and in context of the competitive bid process with its “changing transaction and economic considerations”, Sigma decided not to go ahead with the proposal.

What does this mean for Sigma?

The Sigma Chair Ray Gunston had the following to say:

Sigma remains confident of our growth prospects without a merger with API and the board and management have continued to focus on longer term growth in our core operations. The Sigma team will keep on working to finalise the completion of our infrastructure upgrade, including our ERP project, and to remain focused on leveraging our infrastructure to create shareholder value.

Notwithstanding some short-term challenges in the current year, we believe the Sigma business base provides a positive longer-term outlook. Sigma’s investments in its operations, and its strong balance sheet and future cash generation, underpin the strategic directions that will be shaped under the leadership of our new CEO Vikesh Ramsunder from February 2022.”

Positives for the Wesfarmers share price

It’s good that Wesfarmers isn’t going to be drawn into a bidding battle for API, as long as no other competing bids emerge.

Wesfarmers says that it plans to invest to strengthen the competitive position of API and its community pharmacy partners by expanding ranges, improving supply chain capabilities and enhancing the online experience for customers.

The company also said that API will provide the basis of a new healthcare division of Wesfarmers and a platform from which to invest and develop capabilities in the growing health, wellbeing and beauty sector.

I think Wesfarmers is one of the best ASX blue chips around, so it’s worthwhile thinking about for steady long-term growth and attractive dividends. But there may be even better ASX dividend shares out there to consider.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content